Personalis, Inc. (NASDAQ:PSNL) Stake Raised by Jane Street Group LLC

Jane Street Group LLC grew its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 144.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 401,314 shares of the company’s stock after buying an additional 237,033 shares during the period. Jane Street Group LLC owned 0.57% of Personalis worth $2,320,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after purchasing an additional 5,654 shares in the last quarter. Olympiad Research LP bought a new stake in Personalis during the fourth quarter worth approximately $59,000. Alpine Global Management LLC bought a new stake in Personalis during the fourth quarter worth approximately $60,000. SG Americas Securities LLC bought a new stake in Personalis during the fourth quarter worth approximately $63,000. Finally, Raymond James Financial Inc. bought a new stake in Personalis during the fourth quarter worth approximately $64,000. Institutional investors own 61.91% of the company’s stock.

Personalis Stock Performance

Shares of PSNL stock opened at $4.89 on Friday. The firm’s 50 day moving average price is $3.74 and its two-hundred day moving average price is $4.47. The stock has a market cap of $431.91 million, a PE ratio of -2.91 and a beta of 1.83. Personalis, Inc. has a 52-week low of $1.14 and a 52-week high of $7.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The business had revenue of $20.61 million for the quarter, compared to analyst estimates of $17.41 million. As a group, sell-side analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PSNL has been the topic of several recent analyst reports. Craig Hallum began coverage on Personalis in a report on Monday, March 17th. They set a “buy” rating and a $8.00 target price on the stock. Guggenheim began coverage on shares of Personalis in a research report on Thursday. They set a “buy” rating and a $6.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and set a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th. Finally, HC Wainwright lifted their price objective on shares of Personalis from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, May 7th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Personalis currently has an average rating of “Buy” and a consensus price target of $7.67.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.